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Objectives. To investigate whether patency of a thin walled 8 mm fluoropassivated Dacron graft was similar to that of
a standard 8 mm PTFE graft for femorofemoral crossover bypass surgery.
Design. A randomised multicentre clinical trial comparing two vascular grafts with participation of 10 departments of
vascular surgery in Denmark, Sweden and Norway.
Patients and methods. 198 patients were randomised to PTFE (n¼ 107) or fluoropolymer-coated Dacron grafts
(n¼ 91), 63% underwent surgery for claudication, 27% for ischaemic rest pain and 10% for tissue loss. The median
follow-up time was 24 months (IQR 19e26 months).
Results. The primary patency rate of the two grafts was similar (log rank test: p¼ 0.35). The primary patency rates (95%
CI) for coated Dacron and PTFE grafts were 92% (86e98) and 94% (89e99) at 12 months and 87% (74e95) and 93%
(87e99) at 24 months, respectively.
Conclusion. In patients with unilateral iliac artery disease not amenable to angioplasty, the femoral-femoral bypass is
durable and effective. No difference in patency was found between the two graft materials (fluoropolymer coated Dacron
and PTFE).
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Femorofemoral crossover bypass surgery has been
used for nearly 4 decades for extra anatomic recon-
structions in patients with unilateral iliac artery dis-
ease. When introduced, the crossover bypass was
reserved for patients with a high surgical risk as an
alternative to aortobifemoral bypass.1,2 Today it is
considered a less invasive alternative when endo-
vascular management is impossible or considered
unfavourable.3,4
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material. Experimental data indicate that PTFE may be
less thrombogenic and have less affinity towards bac-
teria, as compared to Dacron.5e10 Though other studies
have indicate equal performance of PTFE and Dacron,
PTFE has become the preferred graft for infrainguinal
procedures in many centres.11e15 Specific studies in
the femorofemoral position are sparse and so are rand-
omised trials.
A recently developed fluoropolymer coated Dacron
graft (fluoropassivated Dacron) aims at combining
some of the desirable clinical features of Dacron (ease
of handling, freedomof suture hole bleeding and lower
price) with those of PTFE (lower thrombogenicity, less
intimal hyperplasia and less bacterial affinity).16
The objective of this trial was to investigate
whether patency of thin walled 8 mm fluoropassi-
vated Dacron graft was comparable to that ofrved.
432 J. P. Eiberg et al.a standard 8 mm PTFE graft for femorofemoral cross-
over bypass surgery.
Material and Methods
Study design
The study was a prospective multicentre clinical trial
comparing two vascular grafts with participation of
vascular surgical units in Denmark, Sweden and
Norway. The study was conducted in accordance
with the Declaration of Helsinki, with the European
Good Clinical Practice Guidelines, and with the
European EN540 standards for Clinical Trials. The pro-
tocol was approved by the regional ethical committees
in Denmark, Norway and Sweden (KF 01-149/99)
according to local requirements.
Inclusion criteria
Patients scheduled for elective femorofemoral cross-
over bypass surgery for uni-iliac occlusive disease.
Patientswith significant aorto- ordonor-iliac arterydis-
ease were eligible, provided vascular or endovascular
treatment before or in connection with the femoro-
femoral bypass procedure could secure uninhibited
inflow.
Exclusion criteria
Exclusion criteria included: age <18 or >85 years,
pregnancy, patients who could not give fully in-
formed consent in writing, patients with serious con-
comitant medical disease with a life expectancy less
than the span of the study, persons mentally not
able to understand and give fully informed consent,
when adequate follow-up could not be arranged,
emergency surgery for trauma, acute thrombosis or
embolism and a proximal anastomosis above the in-
guinal ligament.
Study centres, length of study
Initially 21 centres, expressed interest, but before the
first patients were included, 6 centres withdrew, due
to logistic or financial reasons. Five other centres with-
drew within the first year after they had enrolled
either none or a few patients. Any patients from these
centres were not included in the study. Therefore we
recruited patients from 10 centres (8 Danish centres,
1 Swedish and 1 Norwegian). Recruitment of patients
started in January 2000 and was terminated afterEur J Vasc Endovasc Surg Vol 32, October 200634 months in November 2002 having recruited 198
patients. Though the initial recruitment period of 18
months was extended by 16 months we were approx-
imately 100 patients short of the number estimated
from the power calculation, due to the participation
of only half the initially planned centres.
The surgical procedure and the graft
For the purpose of this study a femorofemoral bypass
was defined as the insertion of a bypass graft de-
scribed by inverse ‘‘U’’ shape with both anastomoses
to the common, the profunda or the superficial femo-
ral artery of the right and left groin, respectively.
The prostheses used were thin walled fluoropassi-
vated Dacron grafts (a knitted Dacron prosthesis in
which the surface was treated with a fluoropolymer
before sealing with gelatin (Sulzer Vascutek Ltd, In-
chinnan Renfrewshire, Scotland, UK)) and thin walled
expanded polytetrafluouroethylene (PTFE) grafts
(W.L. Gore & Associates Inc., Flagstaff, Arizona,
USA or Impra Inc., Tempe, Arizona, USA). In all cases
8 mm externally supported grafts were used. The
costs of the grafts were comparable (w V740 in
2005) (Personal communication, Vingmed Denmark,
Dec 2005). Patients were enrolled consecutively and
randomisation took place in the operating theatre
after surgical exposure and only when the possibility
of the intended bypass procedure was confirmed.
Assignment to either a PTFE or a fluoropassivated
Dacron graft was determined using sealed envelopes
using computerised block randomisation.
Endpoints and patency evaluation
Primary uncorrected graft patency was the primary
outcome. Procedures performed for disease beyond
the graft and its two anastomoses were not considered
as corrections to improve primary graft patency.
Secondary patency, limb survival, perioperative com-
plications and effect on symptoms were secondary
endpoints.
Patency assessment was based on the following
objective findings: Accepted imaging techniques
(duplex, angiography or MR-angiography) or Doppler
signal with handheld Doppler at two points directly
over a superficially located graft in addition to main-
tenance of ankle-arm index improvement or mainte-
nance of achieved improvement in ankle-arm index
no more than 0.10 below the highest post operative
index or direct observation at operation or post-
mortem examination.
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bectomy, thrombolysis or transluminal angioplasty,
and/or problems with the graft itself or one of its
anastomoses requiring revision, but not a redo-
procedure the graft was considered as having second-
ary patency.
Patients were classified preoperatively and during
follow-up as being asymptomatic, suffering claudica-
tion or suffering critical limb ischaemia.17 Each limb
was considered separately.
Sample size and study period
This study was designed as a non-inferiority study,
i.e. that patency of the fluoro passivated Dacron graft
was not inferior to that of the PTFE graft. Assuming
a 2-year patency rate of PTFE of 75% (based on the
available literature when initiating the study in
19993,18) and an attrition rate over a 2-year period of
25% (20% mortality and 5% lost to follow-up), the
numbers required for 80% power (type two error:
0.2) and 95% confidence (type one error: 0.05) were
150 patients in each group. Based on the number of in-
terested centres and the number of femorofemoral
procedures performed in those centres in the year
1998, we estimated that it would take 18 months to re-
cruit 300 patients.
Follow-up
All patients were evaluated at least on the day after
surgery and on the day of discharge. Thereafter all
patients were assessed at 1, 12, and 24 months for
the current status of symptoms, pulses and ankle
pressures and the graft was examined by hand held
Doppler or duplex-ultrasound, as appropriate. If graft
occlusion was suspected a duplex examination or ar-
teriography was performed. One primary investigator
at each centre was asked to fill in the follow-up forms
at the time of each patient review. Extraordinary visits
were performed in case of any clinical or subjective
deterioration.
Statistical analyses
Analysis was by intention to treat. When appropriate,
the c2-test or Fischer exact test was used for compar-
ison of categorical data, and the Mann-Whitney U-test
for continuous data. Kaplan-Meier statistics were
used for analysis of graft failure and survival, and dif-
ferences between groups were assessed by the log-
rank tests. Multivariate analysis was performed with
Cox proportional-hazards models with stepwisevariable selection. Analyses were performed by the
SPSS statistical software package (SPSS Inc, Chicago,
Illinois, USA).
Results
Patients were randomised to PTFE (n¼ 107) or fluoro-
passivated Dacron (n¼ 91) (see flowchart, Fig. 1). In
total 124 (63%) patients underwent surgery for claudi-
cation, and 72 (37%) for critical limb ischaemia (CLI).
The baseline characteristics are presented in Table 1.
The patients in the two groups did not differ signifi-
cantly with respect to the listed co-morbidity.
Donor limb inflow was improved in 76 (38%) pa-
tients of whom 35 (18%) patients had a preoperative
iliac angioplasty (PTA) while 41 patients (21%) had
a simultaneous intra-operative procedure performed:
iliac PTA in 7, iliofemoral bypass or endarterectomy
in 15, femoral endarterectomy in 15 and other proce-
dures in 4. The patients in the two groups did not dif-
fer significantly with respect to the number of inflow
procedures performed.
The preoperative angiogram allowed runoff assess-
ment in 193 (97%) patients, 86 (45%) of whom re-
vealed occlusion (n¼ 76) or >50% stenoses (n¼ 10)
of the superficial femoral artery (SFA). In this sub-
group of patients, intraoperative outflow procedures
were performed in 39 (45%): a popliteal or crural by-
pass in 17 patients and thrombendarterectomy of the
common and/or profound femoral artery in 22.
30-day results
The 30-day operative mortality was 0.5% (1/198). One
79-year-old female suffered a fatal myocardial infarc-
tion during the first post-operative day. However, 21
patients (11%) suffered a peri-operative (within 30
days) complication. Within the first month, 14 (7%)
patients experienced infectious complications, equally
distributed between the patients groups (Dacron 7
(8%)/PTFE: 7 (7%)): superficial wound infections
occurred in 6 (7%) and 6 (6%) while graft-infections
developed in 1 (1%) and 1 (1%), respectively. Three
patients had thrombosis of graft, 2 had postoperative
bleeding necessitating reoperation and 2 patients suf-
fered thrombosis of a femoro-popliteal bypass of the
recipient limb.
Additionally 3 graft infections occurred within 2, 3
and 12 months postoperatively, giving a incidence of
graft-infections of 2.5% (5/198) and in total 9% (17/
198) having infectious complications. All five patients
with graft infection had their graft removed but none
required amputation.Eur J Vasc Endovasc Surg Vol 32, October 2006
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(n= 4)
 - all due to missing data 
Discontinued intervention 
(n=19)
Reason:
- death: 15
- graft removal: 3
- occlusion:1
Allocated to PTFE
(n=107)
Received allocated intervention 
(n=107)
Did not receive allocated intervention 
(n=0)
Lost to follow-up 
(n=2)
- due to missing data and protocol
violation
Discontinued intervention
(n= 14)
Reason:
- death: 9 
- graft removal: 3 
- occlusion: 2 
Allocated to Dacron 
(n=91)
Received allocated intervention 
(n=91)
Did not receive allocated intervention 
(n=0)
Allocation 
Follow-up
Enrolled n=198
Analysis
Analyzed (n=107)
Excluded from analysis
(n=0)
Analyzed (n=91)
Excluded from analysis
(n=0)
Fig. 1. Flowchart illustrating participants flow through the study.Follow-up
During follow-up, median 24 months (IQR 19e26
months), there were 20 graft failures (10%) (Dacron:
11, PTFE: 9) and 24 (12%) deaths. Another 6 patients
(3%) were lost to follow-up. A further 6 patients had
their graft removed due to graft-infection (n¼ 5) or
graft-occlusion resulting in a redo procedure (n¼ 1)
(Fig. 1). The primary patency rate of the two grafts
was not significantly different (log rank: p¼ 0.35).Eur J Vasc Endovasc Surg Vol 32, October 2006The primary patency rates for fluoropassivated Da-
cron and PTFE grafts were 92% (95%-confidence inter-
val: 86e98) and 94% (89e99) at 12 months and 87%
(74e95) and 93% (87e99) at 24 months, respectively
(Fig. 2, Table 2). Pooling the two groups yielded pa-
tency rates (95%CI) at 12 and 24 months of 92%
(89e96) and 90% (86e95), respectively. Only 4 of 20
occluded grafts were successfully revascularised after
thrombectomy or thrombolysis. Analysis of the oc-
cluded grafts (n¼ 20) revealed that 12 (10%) had
435Femorofemoral Crossover BypassTable 1. Baseline characteristics of 198 femorofemoral bypass
Parameter Fluoro-Dacron PTFE
n 91 107
Age median (IQ-range) 71 (65e76) 68 (61e77)
ABI median (IQ-range) 0.60 (0.50e0.77) 0.60 (0.42e0.88)
Indication surgery Claudication 60 (66%) 66 (62%)
Rest pain 23 (25%) 30 (28%)
Ulcer 8 (9%) 11 (10%)
Male sex 51 (56%) 50 (47%)
Never smoked 8 (9%) 15 (14%)
Diabetes Not using insulin 9 (10%) 9 (8%)
On insulin 1 (1%) 5 (5%)
History of stroke 2 (2%) 3 (3%)
Coronary artery disease 21 (23%) 30 (28%)
Hypertension 31 (34%) 41 (38%)
Renal disease 5 (6%) 7 (7%)
Hyperlipidemia 12 (13%) 21 (20%)
Pulmonary disease 23 (26%) 19 (18%)
Previous amputation 3 (3%) 1 (1%)
Duration of operation (min) median (IQ-range) 105 (85e140) 110 (84e138)been operated on for claudication and 8 (11%) for CLI.
Of those 12 with claudication and graft occlusion,
three eventually had a major amputation while nine
(75%) remained stable or improved. Among those op-
erated on for CLI, 2 underwent major amputation fol-
lowing graft occlusion, while 6 remained clinically
stable or improved. Finally, 2 further patients had
a major amputation due to progression of disease.
Thus, in total seven (3.5%) patients underwent major
amputation (Dacron n¼ 3/PTFE n¼ 4). There were
no cases of donor limb amputation.
Observation time
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y
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Fig. 2. Primary patency of the two graft materials (PTFE and
Fluoropassivated Dacron).Survival (95%CI) in patients operated on for claudi-
cation was 98% (95e100%) and 93% (86e99%) at 12
and 24 months, respectively, as compared to the sur-
vival in patients operated on for critical limb ischae-
mia: 88% (79e97%) and 79% (64e94%) (log rank:
p¼ 0.0068; Hazard ration 3.6 (95%-CI: 1.5e8.8) after
adjustment for gender and age.
Risk factors for graft occlusion
As patency of the two grafts did not differ significantly,
data were pooled for further analysis. Neither indica-
tion for surgery (claudication or critical limb ischaemia)
did not affect patency (log rank: p¼ 0.518) nor did
runoff (0e49% SFA stenosis vs >50% or occlusion of
SFA) (log rank: p¼ 0.143) (Fig. 3). Preoperative donor
iliac PTA was not associated to patency rate (Log
rank: p¼ 0.440). However, endarterectomy of the
donor common femoral artery was associated to an
increased risk of graft failure (log rank: p¼ 0.011,
Hazard ratio 4.1(95%CI 1.4e12.4)).
Table 2. Patency data
Interval
start
(months)
Number
entering
interval
Number
exposed
to risk
Kaplan Meyer cumulative
patency at 1, 6, 12 and
24 months. (95%-CI) and {SE}.
Flouropassivated Dacron
0 91 88 98% (95e100%) {0.02}
6 80 80 95% (90e100%) {0.02}
12 76 74 92% (86e98%) {0.03}
18þ 69 63 87% (74e95%) {0.04}
PTFE
0 107 104 100% (100e100%) {0}
6 97 95 97% (94e100%) {0.02}
12 90 87 94% (89e99%) {0.03}
18þ 82 73 93% (87e99%) {0.03}
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436 J. P. Eiberg et al.Symptoms and pressures
Recipient limb ankle-brachial index increased from
a median of 0.41 (interquartile range: 0.30e0.54) pre-
operatively to 0.80 (0.64e0.96) and 0.80 (0.62e0.95)
at 12 and 24 months, respectively (Fig. 4). A total of
75% and 77% patients were reported to be free of
symptoms at 12 and 24 months respectively (Fig. 5).
Donor limb ankle-brachial index remained un-
changed, from a preoperative median value of 0.82
0 6 12 18 24
100 %
80 %
60 %
40 %
20 %
0
Log-Rank: P = 0.143
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y
> 50% stenosis or occlusion
< 50% stenosis
Observation time (months)
Fig. 3. Patency according to the severity of SFA disease.
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Fig. 4. Development in ankle brachial index (ABI) in donor
(C) and recipient (-) leg (mean and interquartile range).Eur J Vasc Endovasc Surg Vol 32, October 2006(0.64e0.99) to 0.82 (0.64e1.00) and 0.82 (0.60e1.00)
at 12 and 24 months, respectively (Fig. 4). Preopera-
tively, 78% reported no symptoms related to the donor
limb, compared with 79% and 80% at 12 and 24
months postoperatively. One month postoperatively
17 patients (9%) reported onset or worsening of is-
chaemic symptoms of the donor limb.
Discussion
Patency and survival
This trial found that a fluoropassivated Dacron graft
performed as well as a standard PTFE graft used in
the femorofemoral position. Moreover, the crossover
bypass seemed durable and effective for treating pa-
tients with uni-iliac occlusive disease. In fact, results
obtained in patients with critical limb ischaemia
equalled those obtained in patients with claudication,
although survival was inferior in the former group, as
expected19 (Table 3). However, the study was under-
powere, as we did not reach the planned number of
patients, in spite of a prolonged period of patient
recruitment.
Only a few studies have compared different graft
material for femorofemoral grafts. In 1999, Johnson
et al. found no difference in patency of PTFE and pre-
clotted knitted Dacron grafts in a randomised trial.20
For many simple Dacron is the gold standard for fem-
oro femoral bypass and a 3rd arm of simple Dacron
would have been tempting but unrealistic due to in-
sufficient available patients. In the only recent rando-
mised controlled trial, Johnson et al. reported the 2
year patency of simple Dacron as 68% (n¼ 340, CLI:
72%).20 A retrospective study found a 2 year patency
of Dacron of 79% (n¼ 86, 48% CLI).18 When pooling
patients who received Dacron and patients who
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
Preop Discharge 1 month 12 month 24 month
no sympt CI CLI
Fig. 5. Effect on ischaemic symptoms following femorofe-
moral bypass surgery (CI: claudication intermittence; CLI:
critical limb ischemia).
437Femorofemoral Crossover BypassTable 3. Primary patency of femorofemoral bypass reported in recent literature
n Primary patency
Critical Limb Ischaemia/
Claudication
Survival
Critical Limb Ischaemia/
Claudication
1 year 2 years 1 year 2 years
Criado 199318 110 88%/82% 74%/75% 90%a 84%a
Johnson 199920 340 78%a 68%a
Purcell 200524 144 88%/93% 82%/92% 86%/99% 67%/97%
Kim 200526 192 86%/95% 73%/90%
Eiberg 2006 198 90%/95% 90%/90% 88%/98% 79%/93%
a Both CLI and claudicants.received PTFE, the patency rate of the crossover-by-
pass in our study (90% at 2y) is comparable with
both the unilateral iliac bypass (92% at 2y) and the
aorto-bifemoral bypass (91% at 2y) as reported by
van der Vliet et al. in an retrospective review of 184 uni-
lateral and 350 aorto-bifemoral reconstructions for ob-
structive disease.21
Risk factors
Over the years several risk factors for femorofemoral
bypass graft failure have been analysed. Indication
for surgery, quality of inflow, superficial femoral ar-
tery outflow and more recently hypertension have
been identified, though results are not consis-
tent.18,22e26 In our prospective study no correlation
between patency and any of the co-variables listed
in Table 1 was observed.
Complications
Ever since the introduction of the femorofemoral by-
pass deterioration of donor limb haemodynamics
causing a ‘‘steal syndrome’’ has been a concern.4,27
In our study 9% reported new or worsening of ischae-
mic symptoms in the donor limb, though no signi-
ficant reduction of ABI was recorded. These new
donor limb symptoms represent both ‘‘silent’’ arterial
insufficiency of the donor limb becoming apparent
when the recipient leg was improved, real haemo-
dynamic steal as well as progression of the athero-
sclerotic process. These results are comparable with
others reporting progression of donor limb symptoms
in approximately 10%.28 More than one third (38%)
had an additional inflow improving procedure ex-
plaining why 14% experienced clinical improvement
of both limbs.
Though infectious complications occurred in 9%
the frequency of graft-infections was only 2.5%, com-
parable with results reported in the literature.20,23There was no evidence to indicate a higher rate of in-
fectious complications with Dacron grafts as com-
pared with PTFE, corroborating other randomised
prospective clinical trials.10,14,15,20 However, the abso-
lute number graft-related complications were low and
this randomised study was probably not large enough
to detect a difference between Dacron and PTFE.
The major limitation of this trial is the risk of over-
looking a smaller difference (type ll error) due to
under-recruitment, a fact that weakens our conclu-
sions. Nevertheless, the present study is one of the
largest controlled femorofemoral bypass trials ob-
tained within a relative short recruitment-period. In
previous trials, comparing two graft materials for
femoro-femoral bypass20 and femoropopliteal by-
pass11,29 approximately 200 patients were found to
be sufficient, according to power calculations.
Because the randomisation was stratified per
centre, the imbalance between the sizes of the two
arms (91/107) may be a consequence of the unexpect-
edly low number of patients being recruited in some
centres.
Although vascular imaging is the gold standard
for determining patency, only two of the participating
centres had duplex-ultrasound for routine follow-up
of crossover bypass. Instead continued improvements
in the ankle-arm index and/or Doppler insonation
directly over the graft was considered to indicate
patency, both methods that are generally
acceptable.17,20
Although our trial was under-recruited and hence
underpowered, we found that fluoropassivated
Dacron grafts performed as well as PTFE grafts for
femorofemoral cross-over bypass surgery, both
having excellent patency at up to 2 years.
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